Patient Portal

John F. DiPersio, MD, PhD

Virginia E. and Samuel J Golman Endowed Professorship of Medicine, Pathology & Immunology
Professor, Pediatrics
Professor, Pathology
Chief, Division of Oncology
Deputy Director, Siteman Cancer Center

Specialty Areas

Bone Marrow Transplant
Hematology
Leukemia
Hematologic Malignancies
Gene Therapy

Board Certifications

Hematology
Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Hematology, oncology, bone marrow transplantation, hematopoietic stem cell transplantation, molecular biology, cellular biology, leukemia, MDS, aplastic anemia

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures

Location(s)

Location(s)

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-454-8304
Fax: 314-454-7551

Education

Education

Fellowship: Hematology & Oncology, UCLA School of Medicine, Los Angeles, CA 1987
Chief Resident: Internal Medicine, Parkland Memorial Hospital, Dallas, TX 1984
Residency: Internal Medicine, Parkland Memorial Hospital, Dallas, TX 1983
Ph.D.: Microbiology, University of Rochester School of Medicine, Rochester, NY 1980
Medical Degree: University Of Rochester School of Medicine, Rochester, NY 1980
B.A.: Biology, Williams College 1973

Publication & Research

Publication & Research

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila ML, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl B, Kim M, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA
Blood. 2020 Jul 2; pii: blood.2020006619. doi: 10.1182/blood.2020006619.

PMID:
    32614951
    [PubMed - as supplied by publisher]
Related citations


Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease.
Abboud R, Choi J, Ruminski P, Schroeder MA, Kim S, Abboud CN, DiPersio JF
Ther Adv Hematol. 2020; 112040620720914489. doi: 10.1177/2040620720914489.

PMID:
    32537114
    [PubMed]
Related citations


Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.
Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N, Warren SE, Arruda A, Liang Y, Smith TH, Foulds GA, Bailey MD, Gowen-MacDonald J, Muth J, Schmitz M, Cesano A, Pockley AG, Valk PJM, Löwenberg B, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada JK, DiPersio JF, Rutella S
Sci Transl Med. 2020 Jun 3; 12(546)pii: eaaz0463. doi: 10.1126/scitranslmed.aaz0463.

PMID:
    32493790
    [PubMed - in process]
Related citations


Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient.
Oza A, Rettig MP, Powell P, O'Brien K, Clifford DB, Ritchey J, Gehrs L, Hollaway J, Major E, Fehniger TA, Miller CA, Soon-Shiong P, Rock A, DiPersio JF
Blood Adv. 2020 Jun 9; 4(11)2387-2391. doi: 10.1182/bloodadvances.2019000664.

PMID:
    32484854
    [PubMed - in process]
Related citations


The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study.
Rashid N, Slade M, Abboud R, Gao F, DiPersio JF, Westervelt P, Uy G, Stockerl-Goldstein K, Romee R, Schroeder MA
Transpl Int. 2020 May 29; doi: 10.1111/tri.13659.

PMID:
    32468720
    [PubMed - as supplied by publisher]
Related citations


A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
Schroeder MA, Khoury HJ, Jagasia M, Ali H, Schiller GJ, Staser K, Choi J, Gehrs L, Arbushites MC, Yan Y, Langmuir P, Srinivas N, Pratta M, Perales MA, Chen YB, Meyers G, DiPersio JF
Blood Adv. 2020 Apr 28; 4(8)1656-1669. doi: 10.1182/bloodadvances.2019001043.

PMID:
    32324888
    [PubMed - in process]
Related citations


Selective targeting of α4β1 integrin attenuates murine graft versus host disease.
Alahmari B, Cooper ML, Vij K, Ritchey J, Ruminski P, Gao F, Choi J, DiPersio JF
Leukemia. 2020 Mar 9; doi: 10.1038/s41375-020-0786-0.

PMID:
    32152466
    [PubMed - as supplied by publisher]
Related citations


Mobilized peripheral blood: an updated perspective.
Karpova D, Rettig MP, DiPersio JF
F1000Res. 2019; 8pii: F1000 Faculty Rev-2125. doi: 10.12688/f1000research.21129.1.

PMID:
    32025285
    [PubMed - indexed for MEDLINE]
Related citations


Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.
Goldsmith SR, Saif Ur Rehman S, Shirai CL, Vij K, DiPersio JF
Blood Adv. 2019 Dec 10; 3(23)4131-4135. doi: 10.1182/bloodadvances.2019000898.

PMID:
    31821455
    [PubMed - in process]
Related citations


Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML, DiPersio JF
Best Pract Res Clin Haematol. 2019 Dec; 32(4)101097. doi: 10.1016/j.beha.2019.101097.

PMID:
    31779968
    [PubMed - indexed for MEDLINE]
Related citations


Ruxolitinib for steroid-refractory acute graft-versus-host disease.
Toama W, Fiala M, Pusic I, Westervelt P, Dipersio JF, Schroeder M
Transpl Int. 2020 Feb; 33(2)244-246. doi: 10.1111/tri.13560.

PMID:
    31755139
    [PubMed - in process]
Related citations


Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL
Haematologica. 2020 Aug; 105(8)e404-e407. doi: 10.3324/haematol.2019.236810.

PMID:
    31753931
    [PubMed - in process]
Related citations


The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.
Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, Romee R
Biol Blood Marrow Transplant. 2020 Jan; 26(1)123-131. doi: 10.1016/j.bbmt.2019.09.024.

PMID:
    31563575
    [PubMed - in process]
Related citations


GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.
Crees ZD, Stockerl-Goldstein K, Vainstein A, Chen H, DiPersio JF
Future Oncol. 2019 Nov; 15(31)3555-3563. doi: 10.2217/fon-2019-0380.

PMID:
    31495201
    [PubMed - indexed for MEDLINE]
Related citations


A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM
Clin Cancer Res. 2019 Dec 1; 25(23)7004-7013. doi: 10.1158/1078-0432.CCR-19-0438.

PMID:
    31481504
    [PubMed - in process]
Related citations


The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation.
Jacobs MT, Olson M, Ferreira BP, Jin R, Hachem R, Byers D, Witt C, Ghobadi A, DiPersio JF, Pusic I
Am J Transplant. 2020 Feb; 20(2)589-592. doi: 10.1111/ajt.15579.

PMID:
    31446673
    [PubMed - in process]
Related citations


Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y
Biol Blood Marrow Transplant. 2019 Dec; 25(12)2305-2321. doi: 10.1016/j.bbmt.2019.08.015.

PMID:
    31446199
    [PubMed - in process]
Related citations


A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.
Ghobadi A, Fiala MA, Rettig M, Schroeder M, Uy GL, Stockerl-Goldstein K, Westervelt P, Vij R, DiPersio JF
Clin Lymphoma Myeloma Leuk. 2019 Oct; 19(10)e588-e593. doi: 10.1016/j.clml.2019.04.017.

PMID:
    31358485
    [PubMed - in process]
Related citations


Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK
Bone Marrow Transplant. 2019 Nov; 54(11)1868-1880. doi: 10.1038/s41409-019-0451-2.

PMID:
    31092900
    [PubMed]
Related citations


Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells.
Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Gao F, Eissenberg LG, Heier RF, Arnett SD, Meyers MJ, Prinsen MJ, Griggs DW, Trumpp A, Ruminski PG, Morrow DM, Bonig HB, Link DC, DiPersio JF
J Clin Invest. 2019 May 14; 129(7)2745-2759. doi: 10.1172/JCI124738.

PMID:
    31085833
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2019:

Company Name: Magenta Therapeutics

Royalties:

Equity: Yes

Consulting/Advisory Board: $1 - $9,999

Speaker Fees:

Reporting Date: May 01, 2020


Company Name: WUGEN

Royalties:

Equity: Yes

Consulting/Advisory Board:

Speaker Fees:

Reporting Date: May 01, 2020